Stock Scorer

Goldenwell Biotech, Inc. (GWLL)

Goldenwell Biotech, Inc. reported revenue of 0 USD for the quarter ending 30 June 2026.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q2 '26 · ending 30 June 2026 0 —
Gross Profit Q2 '26 · ending 30 June 2026 0 —
Operating Income Q2 '26 · ending 30 June 2026 -34.8K —
Net Income Q2 '26 · ending 30 June 2026 -36.9K —
Cost of Revenue Q2 '26 · ending 30 June 2026 0 —
Operating Cash Flow Q2 '26 · ending 30 June 2026 -47.3K -179.6%
Shares Outstanding Q2 '26 · ending 30 June 2026 99M +0.0%
EPS Q1 '25 · ending 31 March 2025 0.00 —

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-12-31 55-113.3K-296.5K—
20242024-12-31 139-123.1K-131.5K—
20232023-12-31 1.8K-115.8K-117.4K—
20222022-12-31 47.8K-985.1K-985.1K—
20212021-12-31 16K-118.3K-117K—
20202020-12-31 0—-6.3K—
20192019-12-31 0—-2.3K—

Every period

Revenue Quarterly

PeriodEndingRevenue
Q2 '262026-06-300
Q1 '262026-03-310
Q4 '252025-12-3155
Q3 '252025-09-300
Q2 '252025-06-300
Q1 '252025-03-310
Q4 '242024-12-310
Q3 '242024-09-300
Q2 '242024-06-30139
Q1 '242024-03-310
Q4 '232023-12-31260
Q3 '232023-09-30382
Q2 '232023-06-30276
Q1 '232023-03-311.4K
Q4 '222022-12-310
Q3 '222022-09-3043.7K
Q2 '222022-06-303.7K
Q1 '222022-03-31397
Q4 '212021-12-314.9K
Q3 '212021-09-3012.2K

Gross Profit Quarterly

PeriodEndingGross Profit
Q2 '262026-06-300
Q1 '262026-03-310
Q4 '252025-12-3112
Q3 '252025-09-300
Q2 '252025-06-300
Q1 '252025-03-310
Q4 '242024-12-310
Q3 '242024-09-300
Q2 '242024-06-3070
Q1 '242024-03-310
Q4 '232023-12-3173
Q3 '232023-09-30186
Q2 '232023-06-30138
Q1 '232023-03-31711
Q4 '222022-12-310
Q3 '222022-09-3023K
Q2 '222022-06-302K
Q1 '222022-03-31209
Q4 '212021-12-312.6K
Q3 '212021-09-306.4K

Operating Income Quarterly

PeriodEndingOperating Income
Q2 '262026-06-30-34.8K
Q1 '262026-03-31-31.3K
Q4 '252025-12-31-22.9K
Q3 '252025-09-30-25.8K
Q2 '252025-06-30-28.2K
Q1 '252025-03-31-36.4K
Q4 '242024-12-31-25.4K
Q3 '242024-09-30-21K
Q2 '242024-06-30-47.8K
Q1 '242024-03-31-29K
Q4 '232023-12-31-20.8K
Q3 '232023-09-30-35.4K
Q2 '232023-06-30-27.1K
Q1 '232023-03-31-33.6K
Q4 '222022-12-31-920.3K
Q3 '222022-09-30-4.6K
Q2 '222022-06-30-26.8K
Q1 '222022-03-31-33.4K
Q4 '212021-12-31-100.3K
Q3 '212021-09-30-88.7K

Net Income Quarterly

PeriodEndingNet Income
Q2 '262026-06-30-36.9K
Q1 '262026-03-31-17.6K
Q4 '252025-12-31-199.7K
Q3 '252025-09-30-27.9K
Q2 '252025-06-30-30.3K
Q1 '252025-03-31-38.5K
Q4 '242024-12-31-27.5K
Q3 '242024-09-30-23.1K
Q2 '242024-06-30-49.9K
Q1 '242024-03-31-31K
Q4 '232023-12-31-20.8K
Q3 '232023-09-30-35.4K
Q2 '232023-06-30-27.1K
Q1 '232023-03-31-33.6K
Q4 '222022-12-31-920.3K
Q3 '222022-09-30-4.6K
Q2 '222022-06-30-26.8K
Q1 '222022-03-31-33.4K
Q4 '212021-12-31-29.5K
Q3 '212021-09-30-87.4K

Cost of Revenue Quarterly

PeriodEndingCost of Revenue
Q2 '262026-06-300
Q1 '262026-03-310
Q4 '252025-12-3143
Q3 '252025-09-300
Q2 '252025-06-300
Q1 '252025-03-310
Q4 '242024-12-310
Q3 '242024-09-300
Q2 '242024-06-3069
Q1 '242024-03-310
Q4 '232023-12-31187
Q3 '232023-09-30196
Q2 '232023-06-30138
Q1 '232023-03-31711
Q4 '222022-12-310
Q3 '222022-09-3020.7K
Q2 '222022-06-301.8K
Q1 '222022-03-31188
Q4 '212021-12-312.3K
Q3 '212021-09-305.8K

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q2 '262026-06-30-47.3K
Q1 '262026-03-31-13.4K
Q4 '252025-12-31-18.8K
Q3 '252025-09-30-30.9K
Q2 '252025-06-3059.4K
Q1 '252025-03-31-32.3K
Q4 '242024-12-31-25.4K
Q3 '242024-09-30-21K
Q2 '242024-06-30-47.8K
Q1 '242024-03-31-29K
Q4 '232023-12-31-19.1K
Q3 '232023-09-30-35.2K
Q2 '232023-06-30-26.9K
Q1 '232023-03-31-31.9K
Q4 '222022-12-31-917.1K
Q3 '222022-09-3015.2K
Q2 '222022-06-30-25K
Q1 '222022-03-31-145.7K
Q4 '212021-12-31-19.4K
Q3 '212021-09-30-12.5K

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q2 '262026-06-3099M
Q1 '262026-03-3199M
Q4 '252025-12-3199M
Q3 '252025-09-3096.4M
Q2 '252025-06-3099M
Q1 '252025-03-3199M
Q4 '242024-12-3199M
Q3 '242024-09-3096.4M
Q2 '242024-06-3096.4M
Q1 '242024-03-3199M
Q2 '232023-06-3096.4M
Q2 '222022-06-3091.3M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q1 '252025-03-310.00
Q4 '242024-12-310.00
Q4 '212021-12-310.00
Q3 '212021-09-300.00
Q2 '212021-06-300.00
Q1 '212021-03-310.00
Q4 '202020-12-310.00
Q3 '202020-09-300.00
Q2 '202020-06-300.00